RIP1/RIP3/MLKL Mediates Myocardial Function Through Necroptosis in Experimental Autoimmune Myocarditis

Area of Science:

• Cardiology
• Cell Biology
• Immunology

Background:

• Viral myocarditis can lead to dilated cardiomyopathy (DCM).
• While apoptosis was considered the primary cell death pathway, necroptosis is increasingly recognized for its role in cardiomyocyte death.
• The interplay between necroptosis, apoptosis, and autophagy in myocarditis requires further investigation.

Purpose of the Study:

• To investigate the role and interdependency of necroptosis, apoptosis, and autophagy in a rat model of experimental autoimmune myocarditis (EAM).
• To assess the therapeutic potential of targeting necroptosis in inflammatory myocarditis.

Main Methods:

• An EAM rat model was established using porcine cardiac myosin (PCM) injection.
• Rats were treated with necroptosis inhibitor Necrostatin-1 (Nec-1), autophagy inhibitor 3-Methyl Adenine (3-MA), or Caspase 8 inhibitor zVAD-fmk.
• Cardiac condition, cell death pathways, and inflammatory infiltration were evaluated.

Main Results:

• EAM rats exhibited increased necroptosis, apoptosis, and autophagy, correlating with cardiac deterioration and inflammation.
• Nec-1 treatment reduced necroptosis, shifted cell death towards apoptosis, and improved cardiac condition without affecting autophagy.
• 3-MA increased necroptosis, indicating compensatory mechanisms.
• zVAD-fmk blocked apoptosis but increased necroptosis and autophagy.

Conclusions:

• All three cell death pathways (necroptosis, apoptosis, autophagy) are upregulated in EAM and contribute to cardiac damage.
• Targeting necroptosis with Nec-1 demonstrates therapeutic potential for inflammatory myocarditis by reducing inflammation and improving cardiac function.
• Nec-1 represents a promising therapeutic strategy for inflammatory myocarditis, potentially avoiding interference with essential apoptosis and autophagy processes.